- Home
- TAC vs LEGN Comparison
TAC vs LEGN Comparison
Compare TAC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAC
- LEGN
- Stock Information
- Founded
- TAC 1909
- LEGN 2014
- Country
- TAC Canada
- LEGN United States
- Employees
- TAC N/A
- LEGN N/A
- Industry
- TAC Electric Utilities: Central
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- TAC Utilities
- LEGN Health Care
- Exchange
- TAC Nasdaq
- LEGN Nasdaq
- Market Cap
- TAC 5.1B
- LEGN 5.9B
- IPO Year
- TAC N/A
- LEGN 2020
- Fundamental
- Price
- TAC $14.71
- LEGN $30.33
- Analyst Decision
- TAC Strong Buy
- LEGN Strong Buy
- Analyst Count
- TAC 4
- LEGN 13
- Target Price
- TAC $21.63
- LEGN $72.92
- AVG Volume (30 Days)
- TAC 2.3M
- LEGN 1.2M
- Earning Date
- TAC 11-06-2025
- LEGN 11-12-2025
- Dividend Yield
- TAC 1.23%
- LEGN N/A
- EPS Growth
- TAC N/A
- LEGN N/A
- EPS
- TAC N/A
- LEGN N/A
- Revenue
- TAC $1,783,342,546.00
- LEGN $909,045,000.00
- Revenue This Year
- TAC N/A
- LEGN $68.68
- Revenue Next Year
- TAC N/A
- LEGN $48.49
- P/E Ratio
- TAC N/A
- LEGN N/A
- Revenue Growth
- TAC N/A
- LEGN 74.75
- 52 Week Low
- TAC $7.82
- LEGN $27.34
- 52 Week High
- TAC $17.88
- LEGN $45.30
- Technical
- Relative Strength Index (RSI)
- TAC 39.30
- LEGN 33.91
- Support Level
- TAC $13.52
- LEGN $29.92
- Resistance Level
- TAC $15.98
- LEGN $33.50
- Average True Range (ATR)
- TAC 0.74
- LEGN 1.33
- MACD
- TAC -0.39
- LEGN -0.10
- Stochastic Oscillator
- TAC 26.52
- LEGN 10.89
About TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse and growing fleet of electrical power generation assets in Canada, the United States, and Australia. The company has six reportable segments namely, Hydro, Wind & Solar, Energy Marketing, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.